Click here to close now.




















Welcome!

News Feed Item

Coronary Thrombosis Global Clinical Trials Review, H2, 2014

LONDON, Sept. 1, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Coronary Thrombosis Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/652973/Coronary-Thrombosis-Global-Clinical-Trials-Review-H2-2014.html

Coronary Thrombosis Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Coronary Thrombosis Global Clinical Trials Review, H2, 2014" provides data on the Coronary Thrombosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Coronary Thrombosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Coronary Thrombosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2

List of Tables 3
List of Figures 4
Introduction 5
Coronary Thrombosis 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Clinical Trials by G7 Countries: Proportion of Coronary Thrombosis to Cardiovascular Clinical Trials 12
Clinical Trials by Phase in G7 Countries 13
Clinical Trials in G7 Countries by Trial Status 14
Clinical Trials by E7 Countries: Proportion of Coronary Thrombosis to Cardiovascular Clinical Trials 15
Clinical Trials by Phase 16
In Progress Trials by Phase 17
Clinical Trials by Trial Status 18
Clinical Trials by End Point Status 19
Unaccomplished Trials of Coronary Thrombosis 20
Subjects Recruited Over a Period of Time 21
Clinical Trials by Sponsor Type 22
Prominent Drugs 23
Clinical Trial Overview of Top Institutes / Government 24
Hopital de la Timone 24
Clinical Trial Overview of Hopital de la Timone 24
Fujian Provincial Hospital 25
Clinical Trial Overview of Fujian Provincial Hospital 25
Herz-Zentrum Bad Krozingen 26
Clinical Trial Overview of Herz-Zentrum Bad Krozingen 26
University of Zurich 27
Clinical Trial Overview of University of Zurich 27
NHS Greater Glasgow and Clyde 28
Clinical Trial Overview of NHS Greater Glasgow and Clyde 28
Samsung Medical Center 29
Clinical Trial Overview of Samsung Medical Center 29
Hamilton Health Sciences 30
Clinical Trial Overview of Hamilton Health Sciences 30
Odense University Hospital 31
Clinical Trial Overview of Odense University Hospital 31
Universitaire Ziekenhuizen Leuven 32
Clinical Trial Overview of Universitaire Ziekenhuizen Leuven 32
Assistance Publique - Hopitaux de Paris 33
Clinical Trial Overview of Assistance Publique - Hopitaux de Paris 33
Five Key Clinical Profiles 34
Appendix 51
Abbreviations 51
Definitions 51
Research Methodology 52
Secondary Research 52
About GlobalData 53
Contact Us 53
Disclaimer 53
Source 53

List of Tables
Coronary Thrombosis Therapeutics, Global, Clinical Trials by Region, 2014* 6
Coronary Thrombosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Coronary Thrombosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Coronary Thrombosis Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 9
Coronary Thrombosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 10
Coronary Thrombosis Therapeutics Clinical Trials, North America, Top Countries, 2014* 11
Proportion of Coronary Thrombosis to Cardiovascular Clinical Trials, G7 Countries (%), 2014* 12
Coronary Thrombosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 13
Coronary Thrombosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 14
Proportion of Coronary Thrombosis to Cardiovascular Clinical Trials, E7 Countries (%), 2014* 15
Coronary Thrombosis Therapeutics, Global, Clinical Trials by Phase, 2014* 16
Coronary Thrombosis Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 17
Coronary Thrombosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 18
Coronary Thrombosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 19
Coronary Thrombosis Therapeutics, Global, Terminated Clinical Trials, 2014* 20
Coronary Thrombosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 21
Coronary Thrombosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 22
Coronary Thrombosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 23
Coronary Thrombosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Hopital de la Timone, 2014* 24
Coronary Thrombosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Fujian Provincial Hospital, 2014* 25
Coronary Thrombosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Herz-Zentrum Bad Krozingen, 2014* 26
Coronary Thrombosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Zurich, 2014* 27
Coronary Thrombosis Therapeutics Clinical Trials Market, Global, Clinical Trials by NHS Greater Glasgow and Clyde, 2014* 28
Coronary Thrombosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Samsung Medical Center, 2014* 29
Coronary Thrombosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Hamilton Health Sciences, 2014* 30
Coronary Thrombosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Odense University Hospital, 2014* 31
Coronary Thrombosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Universitaire Ziekenhuizen Leuven, 2014* 32
Coronary Thrombosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique - Hopitaux de Paris, 2014* 33

List of Figures
Coronary Thrombosis Therapeutics, Global, Clinical Trials by Region (%), 2014* 6
Coronary Thrombosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Coronary Thrombosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Coronary Thrombosis Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 9
Coronary Thrombosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 10
Proportion of Coronary Thrombosis to Cardiovascular Clinical Trials, G7 Countries (%), 2014* 12
Coronary Thrombosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 13
Coronary Thrombosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 14
Proportion of Coronary Thrombosis to Cardiovascular Clinical Trials, E7 Countries (%), 2014* 15
Coronary Thrombosis Therapeutics, Global, Clinical Trials by Phase (%), 2014* 16
Coronary Thrombosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 17
Coronary Thrombosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 18
Coronary Thrombosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 21
Coronary Thrombosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 22
GlobalData Methodology 52

Read the full report:
Coronary Thrombosis Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/652973/Coronary-Thrombosis-Global-Clinical-Trials-Review-H2-2014.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Container technology is sending shock waves through the world of cloud computing. Heralded as the 'next big thing,' containers provide software owners a consistent way to package their software and dependencies while infrastructure operators benefit from a standard way to deploy and run them. Containers present new challenges for tracking usage due to their dynamic nature. They can also be deployed to bare metal, virtual machines and various cloud platforms. How do software owners track the usag...
Mobile, social, Big Data, and cloud have fundamentally changed the way we live. “Anytime, anywhere” access to data and information is no longer a luxury; it’s a requirement, in both our personal and professional lives. For IT organizations, this means pressure has never been greater to deliver meaningful services to the business and customers.
SYS-CON Events announced today that MobiDev, a software development company, will exhibit at the 17th International Cloud Expo®, which will take place November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. MobiDev is a software development company with representative offices in Atlanta (US), Sheffield (UK) and Würzburg (Germany); and development centers in Ukraine. Since 2009 it has grown from a small group of passionate engineers and business managers to a full-scale mobi...
In a recent research, analyst firm IDC found that the average cost of a critical application failure is $500,000 to $1 million per hour and the average total cost of unplanned application downtime is $1.25 billion to $2.5 billion per year for Fortune 1000 companies. In addition to the findings on the cost of the downtime, the research also highlighted best practices for development, testing, application support, infrastructure, and operations teams.
There are many considerations when moving applications from on-premise to cloud. It is critical to understand the benefits and also challenges of this migration. A successful migration will result in lower Total Cost of Ownership, yet offer the same or higher level of robustness. In his session at 15th Cloud Expo, Michael Meiner, an Engineering Director at Oracle, Corporation, analyzed a range of cloud offerings (IaaS, PaaS, SaaS) and discussed the benefits/challenges of migrating to each offe...
"We've just seen a huge influx of new partners coming into our ecosystem, and partners building unique offerings on top of our API set," explained Seth Bostock, Chief Executive Officer at IndependenceIT, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
Digital Transformation is the ultimate goal of cloud computing and related initiatives. The phrase is certainly not a precise one, and as subject to hand-waving and distortion as any high-falutin' terminology in the world of information technology. Yet it is an excellent choice of words to describe what enterprise IT—and by extension, organizations in general—should be working to achieve. Digital Transformation means: handling all the data types being found and created in the organizat...
SYS-CON Events announced today that HPM Networks will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. For 20 years, HPM Networks has been integrating technology solutions that solve complex business challenges. HPM Networks has designed solutions for both SMB and enterprise customers throughout the San Francisco Bay Area.
Chuck Piluso presented a study of cloud adoption trends and the power and flexibility of IBM Power and Pureflex cloud solutions. Prior to Secure Infrastructure and Services, Mr. Piluso founded North American Telecommunication Corporation, a facilities-based Competitive Local Exchange Carrier licensed by the Public Service Commission in 10 states, serving as the company's chairman and president from 1997 to 2000. Between 1990 and 1997, Mr. Piluso served as chairman & founder of International Te...
The Software Defined Data Center (SDDC), which enables organizations to seamlessly run in a hybrid cloud model (public + private cloud), is here to stay. IDC estimates that the software-defined networking market will be valued at $3.7 billion by 2016. Security is a key component and benefit of the SDDC, and offers an opportunity to build security 'from the ground up' and weave it into the environment from day one. In his session at 16th Cloud Expo, Reuven Harrison, CTO and Co-Founder of Tufin,...
With SaaS use rampant across organizations, how can IT departments track company data and maintain security? More and more departments are commissioning their own solutions and bypassing IT. A cloud environment is amorphous and powerful, allowing you to set up solutions for all of your user needs: document sharing and collaboration, mobile access, e-mail, even industry-specific applications. In his session at 16th Cloud Expo, Shawn Mills, President and a founder of Green House Data, discussed h...
For IoT to grow as quickly as analyst firms’ project, a lot is going to fall on developers to quickly bring applications to market. But the lack of a standard development platform threatens to slow growth and make application development more time consuming and costly, much like we’ve seen in the mobile space. In his session at @ThingsExpo, Mike Weiner, Product Manager of the Omega DevCloud with KORE Telematics Inc., discussed the evolving requirements for developers as IoT matures and conducte...
One of the hottest areas in cloud right now is DRaaS and related offerings. In his session at 16th Cloud Expo, Dale Levesque, Disaster Recovery Product Manager with Windstream's Cloud and Data Center Marketing team, will discuss the benefits of the cloud model, which far outweigh the traditional approach, and how enterprises need to ensure that their needs are properly being met.
In their session at 17th Cloud Expo, Hal Schwartz, CEO of Secure Infrastructure & Services (SIAS), and Chuck Paolillo, CTO of Secure Infrastructure & Services (SIAS), provide a study of cloud adoption trends and the power and flexibility of IBM Power and Pureflex cloud solutions. In his role as CEO of Secure Infrastructure & Services (SIAS), Hal Schwartz provides leadership and direction for the company.
The Internet of Everything (IoE) brings together people, process, data and things to make networked connections more relevant and valuable than ever before – transforming information into knowledge and knowledge into wisdom. IoE creates new capabilities, richer experiences, and unprecedented opportunities to improve business and government operations, decision making and mission support capabilities.